Latest Breaking News On - Shubham pant - Page 1 : vimarsana.com

Bile Duct Cancer Continues to Respond to Zanidatamab, Per Longer Follow-Up

Zanidatamab continued to lead to responses and improved overall survival in pretreated HER2-positive biliary tract cancer.

United statesDepartment of gastrointestinal medical oncologyUniversity of texas md anderson cancer centerShubham pantGastrointestinal medical oncologyInvestigational cancer therapeuticsPhasei centerCancer center

Zanidatamab exhibits promising efficacy in advanced HER2-positive biliary tract cancer

CHICAGO — Zanidatamab exhibited durable antitumor activity among patients with previously treated advanced HER2-amplified biliary tract cancer, according to results of the phase 2B HERIZON-BTC-01 study presented at ASCO Annual Meeting.More than half of patients who received zanidatamb (Jazz Pharmaceuticals/Zymeworks) monotherapy survived at least a year and median OS exceeded 15 months.

United statesBymark leiserMindy valcarcelUniversity of texas md anderson cancer centerJazz pharmaceuticals zymeworksJazz pharmaceuticalsShubham pantCancer center

Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024

/PRNewswire/ Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced long-term follow-up results, including the first-ever overall survival (OS) findings,.

United statesKristin bhavnaniMohamedtaki abdulaziz tejaniHye jin choiJean phillippe metgesNobuyoshi hiraokaAndrean flynnRob iannoneAsia pacificEuropean medicines agencyJazz pharmaceuticalsDepartment of gastrointestinal medical oncologyBeigene ltdExchange commissionCommission file noAmerican society of clinical oncology

Zanidatamab induces response in refractory HER2-positive biliary tract cancer

Zanidatamab induces response in refractory HER2-positive biliary tract cancer
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

United statesMindy valcarcelBymark leiserJazz pharmaceuticals zymeworksUniversity of texas md anderson cancer centerShubham pantCancer center

KRAS inhibitors: The next frontier beckons

There has been several developments in the KRAS inhibitor space, shaping the KRAS inhibitors of the future.

United statesUnited kingdomBristol myers squibbEli lillyAmgen lumakrasUniversity of california san franciscoEuropean laboratory research innovation groupMd anderson cancer centerResearch innovationCalifornia san franciscoShubham pantGastrointestinal medical oncologyCancer centerMolecular therapeutics research programKarmanos cancer instituteEuropean laboratory research